Tom F. W. Wolfs

Tom F. W. Wolfs

Auto-generated profile, based on publicly available information

Tom F. W. Wolfs

Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2009 in The Journal of Pediatrics
Verified
Journal Article
Open access
MZMarieke M. van der Zalm
Marieke M. van der Zalm
BEBart E. van Ewijk
Bart E. van Ewijk
BWBerry Wilbrink
Berry Wilbrink
CUCuno S.P.M. Uiterwaal
Cuno S.P.M. Uiterwaal
TWTom F.W. Wolfs
Tom F.W. Wolfs
Cornelis K. van der EntCornelis K. van der Ent
Cornelis K. van der Ent
To investigate the occurrence of respiratory pathogens in samples from children with and without respiratory symptoms and to identify whether age and/ or coinfections modify the impact of respiratory pathogens on symptoms. In a prospective longitudinal study, 18 children were sampled biweekly for respiratory pathogens, irrespective of respiratory symptoms. Polymerase chain reaction was performed for 13 respiratory pathogens. Episodes were defined "asymptomatic" if no symptoms of any respiratory tract illness were present between 1 week before and 1 week after sampling. A total of 230 samples were collected. In 56% of the symptomatic episodes, a pathogen was detected, compared with 40% of the asymptomatic episodes (P = .03). Rhinovirus and coronaviruses were most prevalent in both symptomatic and asymptomatic episodes. In the youngest children, 9% of the pathogen-positive episodes were asymptomatic, compared with 36% in the oldest children (P = .01). Multiple pathogens were found in 17% of the symptomatic episodes and in 3% of the asymptomatic episodes (P = .02). Respiratory pathogens are frequently detected in samples from children with no respiratory symptoms. Symptomatic cases occurred more often in younger children and with detections of more than 1 respiratory pathogen.

18 May 2021 in Clinical Pharmacokinetics
Verified
Journal Article
Open access
PDF file
DBDidi Bury
Didi Bury
WTWim J. E. Tissing
Wim J. E. Tissing
EMEline W. Muilwijk
Eline W. Muilwijk
TWTom F. W. Wolfs
Tom F. W. Wolfs
RBRoger J. Brüggemann
Roger J. Brüggemann
Triazoles represent an important class of antifungal drugs in the prophylaxis and treatment of invasive fungal disease in pediatric patients. Understanding the pharmacokinetics of triazoles in children is crucial to providing optimal care for this vulnerable population. While the pharmacokinetics is extensively studied in adult populations, knowledge on pharmacokinetics of triazoles in children is limited. New data are still emerging despite drugs already going off patent. This review aims to provide readers with the most current knowledge on the pharmacokinetics of the triazoles: fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole. In addition, factors that have to be taken into account to select the optimal dose are summarized and knowledge gaps are identified that require further research. We hope it will provide clinicians guidance to optimally deploy these drugs in the setting of a life-threatening disease in pediatric patients.

14 October 2022 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
JCJ. R. de la Court
J. R. de la Court
ABA. H. W. Bruns
A. H. W. Bruns
ARA. H. E. Roukens
A. H. E. Roukens
IBI. O. Baas
I. O. Baas
KSK. van Steeg
K. van Steeg
JHJarom Heijmans
Jarom Heijmans
Introduction This guideline was written by a multidisciplinary committee with mandated members of the Dutch Society for Infectious Diseases, Dutch Society for Hematology, Dutch Society for Medical Oncology, Dutch Association of Hospital Pharmacists, Dutch Society for Medical Microbiology, and Dutch Society for Pediatrics. The guideline is written for adults and pediatric patients. Method The recommendations are based on the answers to nine questions formulated by the guideline committee. To provide evidence-based recommendations we used all relevant clinical guidelines published since 2010 as a source, supplemented with systematic searches and evaluation of the recent literature (2010–2020) and, where necessary, supplemented by expert-based advice. Results For adults the guideline distinguishes between high- and standard-risk neutropenia based on expected duration of neutropenia (> 7 days versus ≤ 7 days). Where possible a distinction has been made between pediatric and adult patients. Conclusion This guideline was written to aid diagnosis and management of patients with febrile neutropenia due to chemotherapy in the Netherlands. The guideline provides recommendation for children and adults. Adults patient are subdivided as having a standard- or high-risk neutropenic episode based on estimated duration of neutropenia. The most important recommendations are as follows. In adults with high-risk neutropenia (duration of neutropenia > 7 days) and in children with neutropenia, ceftazidime, cefepime, and piperacillin–tazobactam are all first-choice options for empirical antibiotic therapy in case of fever. In adults with standard-risk neutropenia (duration of neutropenia ≤ 7 days) the MASCC score can be used to assess the individual risk of infectious complications. For patients with a low risk of infectious complications (high MASCC score) oral antibiotic therapy in an outpatient setting is recommended. For patients with a high risk of infectious complications (low MASCC score) antibiotic therapy per protocol sepsis of unknown origin is recommended.

22 December 2021 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
PDF file
DBDidi Bury
Didi Bury
TWTom F W Wolfs
Tom F W Wolfs
RHRob ter Heine
Rob ter Heine
EMEline W Muilwijk
Eline W Muilwijk
WTWim J E Tissing
Wim J E Tissing
RBRoger J Brüggemann
Roger J Brüggemann
To determine the pharmacokinetics of twice-a-week micafungin prophylaxis in paediatric leukaemic patients to provide the rationale for this approach. Twice-a-week micafungin at a dose of 9 mg/kg (maximum 300 mg) was given during the leukaemic induction treatment with at least one pharmacokinetic assessment. Non-linear mixed-effects modelling was used for analysis. For model building, our paediatric data were strengthened with existing adult data. Monte Carlo simulations were performed with twice-a-week dosing regimens of 5, 7 and 9 mg/kg and flat dosing per weight band. Simulated paediatric exposures were compared with the exposure in adults after a once-daily 100 mg regimen. Sixty-one paediatric patients were included with a median age and weight of 4.0 years (range 1.0–17) and 19.5 kg (range 8.60–182), respectively. A two-compartment model best fitted the data. CL and central Vd were lower (P < 0.01) in paediatric patients compared with adults. Predicted exposures (AUC0–168 h) for the 5, 7 and 9 mg/kg and flat dosing per weight band regimens exceeded the adult reference exposure. All twice-a-week regimens appeared to result in adequate exposure for Candida therapy, with simulated exposures well above the adult reference exposure. These findings provide the rationale for the pharmacokinetic equivalence of twice-a-week and once-daily micafungin regimens. The greater micafungin exposures seem to be caused by a slower-than-anticipated CL in our paediatric leukaemic patients. The generalizability of our results for Aspergillus prophylaxis cannot be provided without assumptions on target concentrations and within-class identical efficacy.

21 October 2023 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
DBDidi Bury
Didi Bury
TWTom F W Wolfs
Tom F W Wolfs
RHRob ter Heine
Rob ter Heine
EMEline W Muilwijk
Eline W Muilwijk
KEKim C M van der Elst
Kim C M van der Elst
RBRoger J M Brüggemann
Roger J M Brüggemann
Objectives: To study the isavuconazole pharmacokinetics in a real-life paediatric cohort and confirm whether the isavuconazole exposures are within the adult exposure range. Furthermore, we are the first to describe unbound isavuconazole pharmacokinetics. Methods: In this prospective, observational study, the isavuconazole dosing regimen was as follows (IV/oral/nasogastric tube): 5.4 mg/kg isavuconazole (maximum 200 mg/dose) three times daily on Days 1 and 2, followed by 5.4 mg/kg isavuconazole (maximum 200 mg/dose) once daily. At least one pharmacokinetic curve was assessed. Non-linear mixed effects modelling was used for analysis. Monte Carlo simulations were performed with the above mentioned maintenance dose for IV administrations and a weight band dosing regimen for oral/nasogastric tube administrations: I) 37 kg (200 mg daily). Results: Seventeen paediatric patients with a median age of 9 years (range 1–17) and median weight of 26.0 kg (range 8.4–78.5) were evaluated. A two-compartment model describing linear pharmacokinetics of the unbound concentrations and saturable protein binding fitted the isavuconazole concentrations best. The absolute bioavailability of isavuconazole was 41.0% (95% CI: 32.4%–50.8%). The median (IQR) simulated exposures (AUC0–24h, SS) of the total isavuconazole concentrations after IV and oral/nasogastric tube administration were 87.7 mg·h/L (70.5–105.1) and 50.3 mg·h/L (39.0–62.4), respectively. The unbound isavuconazole fraction (unbound/total) ranged from 0.5% to 2.3%. Conclusions: This study revealed low bioavailability after nasogastric tube administration with opened capsules. Isavuconazole exposures were in the expected range following IV administration. Total and unbound isavuconazole pharmacokinetics were reported with a 5-fold range in the unbound fraction.

1 September 2025 in Mycopathologia
Verified
Journal Article
Open access
PDF file
AZAnnemarie Zandijk
Annemarie Zandijk
TBTjomme van der Bruggen
Tjomme van der Bruggen
MSMatthias Sipiczki
Matthias Sipiczki
WTWim J. E. Tissing
Wim J. E. Tissing
TWTom F. W. Wolfs
Tom F. W. Wolfs
FHFerry Hagen
Ferry Hagen
Due to the recent unprecedented global rise of Candidozyma auris in hospital environments the members of the Candidozyma haemuli species complex have raised significant interest of clinicians and researchers. Until the finding of C. auris, the species complex did not receive much attention as the known pathogenic species were only rarely encountered in hospitals and clinical diagnostic laboratories. During the past years several new species were described, such as Candidozyma khanbhai and Candidozyma vulturna, that were found to be of clinical importance. Here, we used phylogenetic and phenotypic analyses –including antifungal susceptibility testing– to characterize and describe a new and potentially clinically relevant yeast that we obtained from clinical specimen and flowers, representing the proposed novel species Candidozyma molenica.